Insmed Incorporated
INSM
Κατάταξη σε μετοχές
#1113
Insmed Incorporated operates as a biopharmaceutical enterprise focused on... Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Τιμή μετοχής
$95.81
Κεφαλαιοποίηση
$20.92B
Αλλαγή (1 ημέρα)
0.54%
Αλλαγή (1 έτος)
-42.94%
Χώρα
US
Εμπόριο Insmed Incorporated (INSM)
Κατηγορία
Healthcare
Κέρδη για την Insmed Incorporated (INSM)
Κέρδη τον Jun 2026 TTM: $-869.11M
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της Insmed Incorporated, τα τρέχοντα κέρδη της εταιρείας είναι $-869.11M. Το 2023, η εταιρεία παρουσίασε κέρδη $-747.01M, μείωση σε σύγκριση με των κερδών του 2022 που ήταν $-480.15M. Τα κέρδη που εμφανίζονται σε αυτή τη σελίδα είναι πριν από τόκους και φόρους, γνωστά και ως EBIT.
Ιστορικό κερδών για την Insmed Incorporated από 2000 έως 2026
Κέρδη στο τέλος κάθε έτους
| Έτος | Κέρδη | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $-869.11M | -4.50% |
| 2024 | $-910.07M | 21.83% |
| 2023 | $-747.01M | 55.58% |
| 2022 | $-480.15M | 10.02% |
| 2021 | $-436.41M | 49.10% |
| 2020 | $-292.69M | 15.43% |
| 2019 | $-253.56M | -21.76% |
| 2018 | $-324.08M | 67.98% |
| 2017 | $-192.92M | 9.51% |
| 2016 | $-176.18M | 46.62% |
| 2015 | $-120.15M | 34.13% |
| 2014 | $-89.58M | 56.35% |
| 2013 | $-57.29M | 38.48% |
| 2012 | $-41.37M | -30.66% |
| 2011 | $-59.66M | 838.70% |
| 2010 | $-6.36M | -105.35% |
| 2009 | $118.83M | -858.45% |
| 2008 | $-15.67M | 0.00% |
| 2007 | 0.00 | 0.00% |
| 2006 | 0.00 | 0.00% |
| 2005 | 0.00 | 0.00% |
| 2004 | 0.00 | 0.00% |
| 2003 | 0.00 | -100.00% |
| 2002 | $-36.42M | -2.02% |
| 2001 | $-37.17M | -53.34% |
| 2000 | $-79.66M | 0.00% |
Κέρδη παρόμοιων εταιρειών ή ανταγωνιστών
| Εταιρεία | Κέρδη | Διαφορά Κερδών | Χώρα |
|---|---|---|---|
| $5.27B | -706.93% |
US
|
|
| $-3.09B | 255.19% |
US
|
|
| $-4.02B | 362.11% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -324.44% |
NL
|
